Neoplasms

Symptoms and General Pathology

All Conditions

Blood and Lymph Conditions

Rare Diseases

Neoplasm Metastasis

Syndrome

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Recurrence

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Disease Attributes

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Analgesics

Cytarabine

Mitoxantrone

Cladribine

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Immunologic Factors

Enzyme Inhibitors

Subject's treatment cycle is 30 days. Subject may be treated on an outpatient basis (CLLDAC arm only). In addition, subjects who fail to achieve a CR/CRi after the first 30-day cycle may receive a second cycle of CLLDAC, per the discretion of the treating physician. Subjects who receive this second cycle should begin cycle 2 no later than 49 days after cycle 1.

Subjects will be started on CLAG-M regimen, which consists of the following:

* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;
* Cytarabine 2 gm/m\^2 IV over four hours on days 1-5
* Mitoxantrone 10 mg/m\^2 IV on days 1-3;
* G-CSF at a dose of 300 μg on days 0-5.

Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen

* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;
* Cytarabine 20 mg/m\^2 subcutaneous injection on days 1-10;

Cladribine and Cytarabine (CLLDAC) Regimen

Medical College of Wisconsin Clinical Cancer Center

Ehab Atallah, MD

This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen and followed at periodic intervals to determine the primary and secondary objectives.

STUDY RATIONALE:

The optimal treatment regimen for relapsed/refractory AML and high risk MDS progressing after hypomethylating agents is unknown. Although several chemotherapy options are available, there is no universally accepted regimen to date. Cladribine based salvage regimens have been frequently used at the investigators' center. However, it is uncertain to predict which patients are likely to respond to cladribine-based salvage or experience treatment-related toxicities. While studies have demonstrated that achievement of MRD negative complete remission (CR) is likely to be associated with a better overall survival (OS), there is limited prospective data evaluating the role of minimal residual disease (MRD) in the setting of relapsed/refractory disease. Through this study, the investigators aim to demonstrate the influence of achieving MRD negative CR on survival of patients with relapsed/refractory AML/high risk MDS treated with cladribine-based salvage therapy. In addition to the conventionally used predictive factors, we aim to incorporate pharmacogenomics to assess the efficacy and toxicity of therapy.

PRIMARY OBJECTIVE:

To determine the CR rate and achievement of MRD negativity after treatment with Cladribine based salvage chemotherapy regimen in patients with relapse/refractory AML/high risk MDS.

SECONDARY OBJECTIVES:

1. To determine the progression free survival (PFS) and overall survival (OS) of patients treated with a cladribine based salvage chemotherapy regimen.
2. To study the pharmacogenomics of patients receiving a cladribine based salvage and determine its influence on survival, CR rate and MRD negativity.
3. Determination of disease- or patient-related factors that predict MRD negativity and survival with a cladribine based salvage regimen.

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

The number of participants who achieve MRD CR (see Cheson 2003, Cheson 2006 in the references below).

The number of participants who achieve MRD CR following one cycle of therapy (see Cheson 2003, Cheson 2006 in the references below).

The number of subjects who require a second cycle of CLLDAC.

The number of participants still alive following CLAG-M chemotherapy.

The number of participants who don't experience progressive disease.

Medical College of Wisconsin

Professor, Department of Medicine, Division of Hematology/Oncology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	NCT03150004	Acute Myeloid L... Myelodysplastic...	Cladribine, Cyt... Cladribine and ...	18 Years -	Medical College of Wisconsin
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	NCT03150004	Acute Myeloid L... Myelodysplastic...	Cladribine, Cyt... Cladribine and ...	18 Years -	Medical College of Wisconsin
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	NCT03150004	Acute Myeloid L... Myelodysplastic...	Cladribine, Cyt... Cladribine and ...	18 Years -	Medical College of Wisconsin
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	NCT03150004	Acute Myeloid L... Myelodysplastic...	Cladribine, Cyt... Cladribine and ...	18 Years -	Medical College of Wisconsin

Spots Global Cancer Trial Database for relapse acute myeloid leukemia